Monoclonal Antibody Treatment

Monoclonal antibodies are lab-created proteins that mimic the ones our bodies produce to fight viruses. The antibodies defend the body by blocking viruses from attaching to human cells.

Monoclonal IV therapy is NOT authorized for use in people who:

• Are hospitalized due to COVID-19
• Require oxygen therapy and/or respiratory support due to COVID-19
• Require an increase in baseline oxygen flow rate and/or respiratory support due to COVID-19 and are on chronic oxygen therapy and/or respiratory support due to an underlying non-COVID-19 related comorbidity

Monoclonal IV therapy will be given as an injection through a vein (intravenously or IV) over at least 30 seconds. You will be monitored for at least 1 hour after you receive the treatment.

In order to ensure the safety and comfort of our patients, we offer this treatment in a house call setting.

The side effects of receiving any medicine intravenously may include brief pain, bleeding, bruising of the skin, soreness, swelling, and possible infection at the injection site.

Allergic reactions can happen during and after injection with bebtelovimab. You will be monitored for signs of an allergic reaction, including fever, difficulty breathing, low oxygen level in your blood, chills, tiredness, fast or slow heart rate, chest discomfort pain, weakness, confusion, nausea, headache, shortness of breath, low or high blood pressure, wheezing, swelling of your lips, face, or throat, rash including hives, itching, muscle aches, dizziness, feeling faint, and sweating. These reactions may be severe or life threatening.